Intercell AG announces Q1 2012 results and operational update

Today, Intercell AG (VSE: ICLL) announced the Q1 2012 results and an operational update:


  • Solid IXIARO®/JESPECT® sales revenues up by 36.4% to EUR 4.6m in Q1 2012 compared to Q1 2011
  • Net loss reduced by 28.2% to EUR 8.1m; cash position of EUR 38.5m at quarter end
  • Pseudomonas clinical Phase II/III study initiated - interim futility results expected mid 2013 - other R&D activities on track

For details please see the attached Q1 report.

We cordially invite you to listen to conference call via webcast:

Tuesday, May 8, 2012
2 p.m. CET (1 p.m. BST / 8 a.m. EST)
Chairperson: Thomas Lingelbach, CEO Intercell AG

If you have any further questions please do not hesitate to contact us.

The sender takes full responsibility for the content of this news item. Content may include forward-looking statements which, at the time they were made, were based on expectations of future events. Readers are cautioned not to rely on these forward-looking statements.

As a life sciences organization based in Vienna, would you like us to promote your news and events? If so, please send your contributions to news(at)